- Home
- CTO vs TLRY Comparison
CTO vs TLRY Comparison
Compare CTO & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | TLRY |
|---|---|---|
| Founded | 1902 | N/A |
| Country | United States | Canada |
| Employees | 42 | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 599.1M | 688.9M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CTO | TLRY |
|---|---|---|
| Price | $20.72 | $5.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $22.50 | ★ $72.33 |
| AVG Volume (30 Days) | 290.0K | ★ 6.9M |
| Earning Date | 04-28-2026 | 04-01-2026 |
| Dividend Yield | ★ 7.44% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.63 | $8.79 |
| Revenue Next Year | $2.76 | $19.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.07 | $0.36 |
| 52 Week High | $20.90 | $15.70 |
Technical Indicators
Market Signals| Indicator | CTO | TLRY |
|---|---|---|
| Relative Strength Index (RSI) | 63.77 | 31.10 |
| Support Level | $17.79 | $1.12 |
| Resistance Level | $20.67 | $7.01 |
| Average True Range (ATR) | 0.40 | 0.22 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 79.92 | 8.25 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.